Compare Mesoblast Limited (MESO) vs Twilio Inc (TWLO) Price & Performance

MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.

While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.

Twilio (TWLO) trades at $273.00, down 2.64% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results pending. Revenue growth accelerated to $5.07 billion in 2025, turning net income positive at $33.83 million after prior losses. Recent inclusion in the S&P 500 index highlights institutional recognition, while analyst consensus remains strongly bullish with 76.9% buy ratings.

Outlook is positive given earnings momentum and S&P 500 inclusion, but high valuation multiples (P/E 37.71, EV/EBITDA 80.78) pose risks if growth slows. Competitive pressures in customer engagement software and potential volatility from AI-driven sentiment shifts require monitoring. The stock trades above the consensus price target of $254.65, suggesting near-term consolidation may precede further gains if execution continues.